These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28215942)

  • 1. How to identify and eliminate compounds with a risk of high clinical dose during the early phase of lead optimisation in drug discovery.
    Teague S; Valko K
    Eur J Pharm Sci; 2017 Dec; 110():37-50. PubMed ID: 28215942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro measurement of drug efficiency index to aid early lead optimization.
    Valko K; Chiarparin E; Nunhuck S; Montanari D
    J Pharm Sci; 2012 Nov; 101(11):4155-69. PubMed ID: 22930396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipophilicity and biomimetic properties measured by HPLC to support drug discovery.
    Valkó KL
    J Pharm Biomed Anal; 2016 Oct; 130():35-54. PubMed ID: 27084527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating unbound volume of distribution and tissue binding by in vitro HPLC-based human serum albumin and immobilised artificial membrane-binding measurements.
    Valkó KL; Nunhuck SB; Hill AP
    J Pharm Sci; 2011 Mar; 100(3):849-62. PubMed ID: 20891009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo potency revisited - Keep the target in sight.
    Gabrielsson J; Peletier LA; Hjorth S
    Pharmacol Ther; 2018 Apr; 184():177-188. PubMed ID: 29024741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a novel cytochrome p450 bioaffinity detection system coupled online to gradient reversed-phase high-performance liquid chromatography.
    Kool J; van Liempd SM; Ramautar R; Schenk T; Meerman JH; Irth H; Commandeur JN; Vermeulen NP
    J Biomol Screen; 2005 Aug; 10(5):427-36. PubMed ID: 16093552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of Early Human Dose Prediction: A Key Metric for Compound Progression in Drug Discovery.
    Page KM
    Mol Pharm; 2016 Feb; 13(2):609-20. PubMed ID: 26696327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of volume of distribution in humans from high throughput HPLC-based measurements of human serum albumin binding and immobilized artificial membrane partitioning.
    Hollósy F; Valkó K; Hersey A; Nunhuck S; Kéri G; Bevan C
    J Med Chem; 2006 Nov; 49(24):6958-71. PubMed ID: 17125249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.
    Stringer RA; Strain-Damerell C; Nicklin P; Houston JB
    Drug Metab Dispos; 2009 May; 37(5):1025-34. PubMed ID: 19196847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high throughput metabolic stability screening workflow with automated assessment of data quality in pharmaceutical industry.
    Xu R; Manuel M; Cramlett J; Kassel DB
    J Chromatogr A; 2010 Mar; 1217(10):1616-25. PubMed ID: 20132940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events.
    Shaffer CL; Scialis RJ; Rong H; Obach RS
    Biopharm Drug Dispos; 2012 Mar; 33(2):72-84. PubMed ID: 22213407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipophilicity and biomimetic properties to support drug discovery.
    Tsopelas F; Giaginis C; Tsantili-Kakoulidou A
    Expert Opin Drug Discov; 2017 Sep; 12(9):885-896. PubMed ID: 28644732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive approaches to increase absorption of compounds during lead optimisation.
    Valko K; Butler J; Eddershaw P
    Expert Opin Drug Discov; 2013 Oct; 8(10):1225-38. PubMed ID: 23865945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomimetic modeling of oxidative drug metabolism : Strategies, advantages and limitations.
    Lohmann W; Karst U
    Anal Bioanal Chem; 2008 May; 391(1):79-96. PubMed ID: 18163163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient screening of cytochrome P450 BM3 mutants for their metabolic activity and diversity toward a wide set of drug-like molecules in chemical space.
    Reinen J; van Leeuwen JS; Li Y; Sun L; Grootenhuis PD; Decker CJ; Saunders J; Vermeulen NP; Commandeur JN
    Drug Metab Dispos; 2011 Sep; 39(9):1568-76. PubMed ID: 21673132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes.
    Poulin P; Haddad S
    J Pharm Sci; 2011 Oct; 100(10):4501-17. PubMed ID: 21574165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of in silico models for fraction of unbound drug in human liver microsomes.
    Gao H; Steyn SJ; Chang G; Lin J
    Expert Opin Drug Metab Toxicol; 2010 May; 6(5):533-42. PubMed ID: 20233033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.
    Chen Y; Jin JY; Mukadam S; Malhi V; Kenny JR
    Biopharm Drug Dispos; 2012 Mar; 33(2):85-98. PubMed ID: 22228214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioactivation of isothiazoles: minimizing the risk of potential toxicity in drug discovery.
    Teffera Y; Choquette D; Liu J; Colletti AE; Hollis LS; Lin MH; Zhao Z
    Chem Res Toxicol; 2010 Nov; 23(11):1743-52. PubMed ID: 20825217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.